Israel’s 2bPrecise takes genetic data to help determine the best treatment for individuals; FDA approves Israel’s HemoScreen portable blood test to sell in the US; Israel gives pediatric orthopedic training to 50 African doctors, and much more!

By Michael Ordman

ISRAEL’S MEDICAL ACHIEVEMENTS

The right treatment is in the DNA

Israel’s 2bPrecise takes sources of patient genetic data to help physicians determine the best treatment for individuals. 2bPrecise is partnering with US-based Innovation Institute and Avera Health’s GeneFolio to deliver a pharmacogenomics knowledge base to the point of care.
https://www.businesswire.com/news/home/20181102005411/en/2bPrecise-Honored-Israel%E2%80%99s-Top-Startups  https://www.businesswire.com/news/home/20180307005764/en https://2bprecisehealth.com/

US approval for portable blood test

I reported previously (8th Apr) on Israel’s PixCell which received a multi-million grant by the EU to help advance its HemoScreen portable blood test.  The US FDA has just approved HemoScreen to sell in the USA. Meanwhile, Israel’s SightDx has launched its OLO blood tester.
https://www.prnewswire.com/news-releases/hemoscreen-hematology-analyzer-for-point-of-care-receives-fda-510k-clearance-300745234.html

https://www.sightdx.com/

Pediatric orthopedic training for 50 African doctors

Professor Mark Eidelman of Haifa’s Rambam Medical Center led a unique 4-day training course in Addis Ababa. 50 doctors from Ethiopia and neighboring countries learned how to fix pediatric orthopedic deformities.
http://www.israelnationalnews.com/News/News.aspx/254979

Brain bleed detection approved

I reported previously on Israel’s MedyMatch and its Artificial Intelligent Accipio Ix intracranial hemorrhage detection software.  MedyMatch (renamed MaxQ AI) has now received both FDA and CE approval to sell its systems in both the US and in Europe.
https://www.prnewswire.com/news-releases/maxq-ai-receives-fda-clearance-for-accipio-ix-intracranial-hemorrhage-diagnostics-intelligence-platform-300745201.html

Treatment for advanced Parkinson’s disease

I reported previously (see here) on Israel’s Intec Pharma which is developing treatments based on its innovative Accordion technology.  Intec’s COO Nadav Navon provided an update of Intec’s pipeline on ILTV.  Phase 3 trials have now commenced on Intec’s Parkinson’s treatment.
https://ir.intecpharma.com/news-releases/news-release-details/intec-pharma-completes-enrollment-pivotal-phase-3-clinical-trial